Solid state of a new PDE-5 inhibitor DA-8159: Characterization, dissolution, transformation

被引:0
作者
Ji Yoon Ryu
Young-Taek Sohn
机构
[1] Duksung Women’s University,College of Pharmacy
来源
Archives of Pharmacal Research | 2012年 / 35卷
关键词
DA-8159; Dissolution; Polymorphism; Transformation;
D O I
暂无
中图分类号
学科分类号
摘要
The polymorphic forms of a new PDE-5 inhibitor DA-8159 were prepared and characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD) and thermogravimetric analysis (TG). Two crystal forms and one amorphous form of DA-8159 have been isolated by recrystallization and characterized by DSC, TG and PXRD. From the TG data it was confirmed that two crystal forms are neither solvates nor hydrates. The PXRD patterns of the two crystal forms were different. In the dissolution studies in simulated intestinal fluid at 37 ± 0.5°C, the solubility decreased in the order of amorphous form > Form 1 > Form 2. After storage of 60 days, Form 1 was transformed to Form 2. Form 2 was not transformed. The amorphous form was transformed to Form 2 at 52% R.H. and 95% R.H., but it did not transform at 0% R.H.
引用
收藏
页码:861 / 866
页数:5
相关论文
共 45 条
[1]  
Buckton G.(1995)The use of isothermal microcalorimetry in the study of changes in cristallinity of spray-dried salbutamol sulphate Int. J. Pharm. 116 113-118
[2]  
Darcy P.(2002)A study of the crystallization of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy Int. J. Pharm. 237 171-178
[3]  
Greenleaf D.(1995)Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates Thermochim. Acta 248 1-59
[4]  
Holbrook P.(1997)Polymorphism and thermal analysis of pharmaceutical agents Pharm. Unserer Zeit 26 224-231
[5]  
Columbano A.(1969)Pharmaceutical applications of polymorphism J. Pharm. Sci. 58 911-929
[6]  
Buckton G.(1975)Characterization of habits and crystalline modification of solids and their pharmaceutical applications J. Pharm. Sci. 64 1269-1288
[7]  
Wikeley P.(1988)Fundamentals of pharmaceutics Acta Pharm. Technol. 34 1-10
[8]  
Giron D.(1977)Modifikationsumwandlungen durch mechanische Bearbeitung Pharm. Ind. 39 68-71
[9]  
Grunenberg A.(2003)DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats Arch. Pharm. Res. 26 612-619
[10]  
Haleblian J. K.(2003)Crystalline to amorphous transition of disodium hydrogen phosphate during primary drying Pharm. Res. 20 802-803